Sugi Predict

Sugi Predict / Compounds / SCHEMBL209359

SCHEMBL209359

SCHEMBL209359

COC(=O)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 3/20 0.43
▸ DGAT1 O75907 1/20 0.41
▸ CA1 P00915 5/20 0.40
▸ CA2 P00918 5/20 0.40
▸ CA9 Q16790 5/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ GLA P06280 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ CASP1 P29466 1/20 0.40
▸ CASP7 P55210 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ CSF1R P07333 1/20 0.39
▸ CA12 O43570 2/20 0.39
▸ CA7 P43166 2/20 0.39
▸ CA14 Q9ULX7 2/20 0.39
▸ CA3 P07451 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3416598 0.88 HIF1A (0.43) HIF1ADGAT1CA1CA2CA9
SCHEMBL25035049 0.88 HIF1A (0.43) HIF1ADGAT1CA1CA2CA9
SCHEMBL2792346 0.87 AAK1 (0.44) HIF1ADGAT1CA1CA2CA9
SCHEMBL2782538 0.86 CA1 (0.43) HIF1ACA1CA2CA9KDM4E
SCHEMBL31258763 0.85 CA1 (0.53) HIF1ADGAT1CA1CA2CA9
SCHEMBL3461872 0.85 MEN1 (0.47) HIF1ADGAT1CA1CA2CA9
SCHEMBL2697552 0.85 CA1 (0.53) HIF1ADGAT1CA1CA2CA9
SCHEMBL2362943 0.85 AAK1 (0.45) HIF1ADGAT1CA1CA2CA9
SCHEMBL14513575 0.84 LIPG (0.42) HIF1ACA1CA2CA9CSF1R
SCHEMBL516413 0.84 ROCK1 (0.46) HIF1ADGAT1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125367-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS REMEDY PLAN, INC. (US) 2026-05-07 — — US disclosed
US-20260109690-A1 HDAC6 INHIBITORS AND METHOD OF THEIR USE BAERENKRAFT THERAPEUTICS LLC (US) 2026-04-23 — — US disclosed
US-20260022124-A1 THERAPEUTIC COMPOUNDS AND METHODS UNIV MINNESOTA (US) 2026-01-22 — — US disclosed
US-12522587-B2 Cancer treatments targeting cancer stem cells REMEDY PLAN, INC. (US) 2026-01-13 — — US disclosed
EP-4612140-A1 NEK7 DEGRADERS AND METHODS OF USE THEREOF Captor Therapeutics S.A. (PL) 2025-09-10 — — EP disclosed
EP-3233842-B1 BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARB) AGONISTS KING S COLLEGE LONDON (GB) 2025-03-26 — — EP disclosed
WO-2024148274-A1 COMPLEMENT INHIBITION APELLIS PHARMACEUTICALS, INC. (US) 2024-07-11 — — WO disclosed
WO-2024148274-A1 COMPLEMENT INHIBITION APELLIS PHARMACEUTICALS, INC. (US) 2024-07-11 — — WO disclosed
EP-3377473-B1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2024-06-19 — — EP disclosed
EP-4371982-A2 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX Pharmaceuticals, Inc. (US) 2024-05-22 — — EP disclosed
EP-2215077-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS Prosidion Limited (GB) 2010-08-11 — — EP disclosed
US-7759376-B2 Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity BAYER HEALTHCARE LLC (US) 2010-07-20 — — US disclosed
EP-2197551-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS Merck Sharp & Dohme Corp. (US) 2010-06-23 — — EP disclosed
US-20090209556-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK SHARP & DOHME CORP. 2009-08-20 — — US disclosed
WO-2009050523-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 — — WO disclosed
WO-2009050522-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 — — WO disclosed
WO-2009050523-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 — — WO disclosed
WO-2009050522-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 — — WO disclosed
WO-2009032249-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK & CO., INC. (US) 2009-03-12 — — WO disclosed
US-20070265298-A1 Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity BAYER PHARMACEUTICALS CORPORATION (US) 2007-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265298-A1 Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity FABP4, GPR119, PGC HIF1A 326/4885DGAT1 486/4885CA1 4736/4885
US-20260022124-A1 THERAPEUTIC COMPOUNDS AND METHODS NR5A1, CYP17A1, CNR1 HIF1A 1566/4885DGAT1 1326/4885CA1 205/4885
US-20260125367-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS MCL1, MALT1, BCL6 HIF1A 109/4885DGAT1 1215/4885CA1 31/4885
US-20090209556-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS GUCY1B1, GUCY1A2, GUCY1A1 HIF1A 836/4885DGAT1 1088/4885CA1 4658/4885
US-20260109690-A1 HDAC6 INHIBITORS AND METHOD OF THEIR USE HDAC6, HDAC3, HDAC1 HIF1A 3623/4885DGAT1 2642/4885CA1 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.